Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRZLTRezolute$9.34+6.5%$6.88$2.21▼$9.56$848.17M0.03970,766 shs1.95 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRZLTRezolute-0.45%+6.95%+21.81%+101.61%+77.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRZLTRezolute$9.34+6.5%$6.88$2.21▼$9.56$848.17M0.03970,766 shs1.95 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRZLTRezolute-0.45%+6.95%+21.81%+101.61%+77.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRZLTRezolute 3.14Buy$14.5055.25% UpsideCurrent Analyst Ratings BreakdownLatest RZLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/22/2025RZLTRezoluteGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.009/18/2025RZLTRezoluteMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.009/18/2025RZLTRezoluteWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$12.009/18/2025RZLTRezoluteBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.009/3/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.00(Data available from 9/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRZLTRezoluteN/AN/AN/AN/A$1.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRZLTRezolute-$74.41M-$0.97N/AN/AN/AN/A-65.03%-58.86%11/6/2025 (Estimated)Latest RZLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/17/2025Q4 2025RZLTRezolute-$0.23-$0.26-$0.03-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthRZLTRezoluteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRZLTRezoluteN/A14.3714.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipRZLTRezolute18.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableRZLTRezolute4090.81 million74.11 millionOptionableRZLT HeadlinesRecent News About These CompaniesRezolute (NASDAQ:RZLT) Stock Price Up 7.6% - Still a Buy?1 hour ago | marketbeat.comRezolute (NASDAQ:RZLT) Reaches New 52-Week High - Still a Buy?September 25 at 5:10 AM | marketbeat.comGoldman Sachs Group Inc. Invests $685,000 in Rezolute, Inc. $RZLTSeptember 25 at 3:21 AM | marketbeat.comRezolute (NASDAQ:RZLT) Given "Buy" Rating at GuggenheimSeptember 24 at 2:48 AM | americanbankingnews.comQ3 Earnings Forecast for Rezolute Issued By WedbushSeptember 23 at 2:57 AM | americanbankingnews.comRezolute's (RZLT) "Buy" Rating Reiterated at GuggenheimSeptember 22, 2025 | marketbeat.comWhat is Wedbush's Forecast for Rezolute Q3 Earnings?September 22, 2025 | marketbeat.comHC Wainwright Estimates Rezolute's Q1 Earnings (NASDAQ:RZLT)September 22, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Hits New 52-Week High - Time to Buy?September 20, 2025 | marketbeat.comHC Wainwright Weighs in on Rezolute FY2030 EarningsSeptember 20, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Receives "Outperform" Rating from WedbushSeptember 20, 2025 | americanbankingnews.comRezolute's (RZLT) Outperform Rating Reaffirmed at WedbushSeptember 19, 2025 | marketbeat.comRezolute price target raised to $20 from $15 at MaximSeptember 19, 2025 | msn.comBTIG Research Reiterates "Buy" Rating for Rezolute (NASDAQ:RZLT)September 19, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Earns "Buy" Rating from BTIG ResearchSeptember 19, 2025 | americanbankingnews.comRezolute (NASDAQ:RZLT) Posts Earnings Results, Misses Estimates By $0.04 EPSSeptember 18, 2025 | marketbeat.comRezolute, Inc.: Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business UpdateSeptember 18, 2025 | finanznachrichten.deRezolute, Inc. Reports Fiscal 2025 Financial ResultsSeptember 17, 2025 | tipranks.comRezolute reports Q4 EPS (26c), consensus (23c)September 17, 2025 | msn.comRezolute, Inc. Reports Q4 and Full Year Fiscal 2025 Financial Results and Updates on Ersodetug Development ProgressSeptember 17, 2025 | quiverquant.comQRezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business UpdateSeptember 17, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025What NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave StockBy Nathan Reiff | September 8, 2025NVIDIA Stock Could Pull Back in September, But Don’t Bet on ItBy Thomas Hughes | August 28, 2025Rezolute Stock: FDA Fast Track Fuels 2025 BreakoutBy Thomas Hughes | September 17, 2025RZLT Company DescriptionsRezolute NASDAQ:RZLT$9.34 +0.57 (+6.50%) Closing price 04:00 PM EasternExtended Trading$9.31 -0.03 (-0.32%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Institutional Buying Sets a High Floor for Microsoft Stock High-Momentum ETFs to Mine for Gold, Silver, and Bitcoin It's a Good Time to Build a Position in KB Home Alphabet: Time to Take Profits, Buy, or Wait for a Pullback? NuScale, Rocket Lab Face Heavy Insider Selling After Surges Why Wall Street Is Betting Billions on Oklo's Nuclear Vision CrowdStrike’s Investor Day Sparks Bullish Momentum Cintas Stock Sends a Clear Buy Signal as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
